Status:
COMPLETED
A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
Novartis
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
This study was intended to assess how well inhaled NVA237 opens up the airways of patients with mild, moderate or severe COPD over a 24 hour period after a 14 day treatment period.
Eligibility Criteria
Inclusion
- Male or female aged greater than 40 years with COPD Current or ex-smokers
Exclusion
- Cardiac (heart) disorders, history of asthma, requiring oxygen therapy. Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00856193
Start Date
February 1 2009
End Date
May 1 2009
Last Update
September 14 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Spartanburg Medical Research
Spartanburg, South Carolina, United States, 29303
2
Harrison Clinical Research Deutschland GmbH
Albrechtstrasse 14, Munich, Germany, 80636